US 12,291,726 B2
A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter
Tony R. Reid, San Diego, CA (US); Bryan T. Oronsky, Los Altos Hills, CA (US); and Christopher Larson, San Diego, CA (US)
Assigned to EPICENTRX, INC., La Jolla, CA (US)
Filed by EpicentRx, Inc., La Jolla, CA (US)
Filed on Apr. 29, 2024, as Appl. No. 18/649,467.
Application 18/649,467 is a continuation of application No. 16/604,194, granted, now 11,999,973, previously published as PCT/US2018/026977, filed on Apr. 10, 2018.
Claims priority of provisional application 62/483,837, filed on Apr. 10, 2017.
Prior Publication US 2024/0294883 A1, Sep. 5, 2024
Int. Cl. C12N 5/09 (2010.01); C12N 7/00 (2006.01)
CPC C12N 5/0693 (2013.01) [C12N 7/00 (2013.01); C12N 2710/10321 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10352 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A composition comprising an A549 host cell adapted to suspension culturing in a serum-free medium infected with a recombinant oncolytic adenovirus,
wherein the recombinant oncolytic adenovirus comprises an E1a gene comprising an E1a protein coding region operably linked to a modified regulatory sequence comprising (i) deletion of a functional Pea3 binding site, (ii) deletion of a functional E2F binding site, (iii) deletion of a functional TATA box, (iv) deletion of a functional CAAT box, (v) deletion of the nucleotides corresponding to the nucleotides from 195-244 of the Ad5 genome (SEQ ID NO: 1), or (vi) has two, three, or four of (i), (ii), (iii), and (iv).